Novo Nordisk's third quarter report once again shows the industry the market potential of the star product Smeaglutide. On November 6th, Novo Nordisk released its third quarter report showing a year-on-year revenue growth of 23%, with the largest growth driven by semaglutide, accounting for 69% of Novo Nordisk's revenue. At the same time as the global release of its third quarter report, Novo Nordisk is showcasing its major product, semaglutide, at the CIIE. The first exhibition in China includes the world's first and currently only GLP-1 receptor agonist, semaglutide tablets (trade name: Novozymes), and the world's first GLP-1 weekly formulation for long-term weight management, Novozymes, also known as semaglutide injection for long-term weight management.
Zhou Xiaping, Senior Vice President of Novo Nordisk Global and President of Greater China, stated that Novo Nordisk has been continuously leading the research and development breakthroughs of GLP-1 drugs. At this CIIE, Novo Nordisk launched the "Healthy China Action - Metabolic Renewal Year" campaign. Through the CIIE platform, Novo Nordisk has witnessed numerous innovative drugs accelerating their landing in China and even obtaining approval simultaneously, completing the transformation from "exhibits" to "commodities", and also achieving pioneering innovation in public science education.
In addition, in terms of financial reports, in a single quarter, Novo Nordisk's third quarter revenue was 71.311 billion Danish kroner, a year-on-year increase of 22%, and net profit was 27.301 billion Danish kroner, a year-on-year increase of 21%, higher than market expectations. Affected by the above news, Novo Nordisk rose by over 6% before the stock market opened on November 6th. Overall, in the first three quarters, Novo Nordisk's revenue was KRK 204.72 billion, a year-on-year increase of 23%; Net profit was 72.758 billion Danish kroner, an increase of 18% year-on-year.